Interaction Checker

Interações de Icosapente etílico

Icosapente etílico (Vascepa), ácido graxo ômega-3, tem 33 interações documentadas nas bulas da FDA e nas fichas informativas que indexamos (graves: 0; moderadas: 33; leves: 0; casos em que uma bula relata não haver interação significativa: 0). Cada item abaixo cita a frase em que se baseia. Esta página de medicamento é um ponto de partida, não um veredito para a sua situação.

Interações segundo a bula

Interações moderadas (33)

  • Ácido acetilsalicílicoAINEModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

  • Ácido acetilsalicílico + dipiridamolantiagregante plaquetárioModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

  • Anlodipino + atorvastatinabloqueador dos canais de cálcio di-hidropiridínicoModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • ApixabanaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • ArgatrobanaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • AtorvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • BivalirudinaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Butalbital + ácido acetilsalicílico + cafeínabarbitúricoModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

  • Butalbital + ácido acetilsalicílico + cafeína + codeínabarbitúricoModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

  • Cangrelorantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Cilostazolantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Clopidogrelantiagregante plaquetárioModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

  • DabigatranaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Dipiridamolantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • EdoxabanaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • EnoxaparinaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Eptifibatidaantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Ezetimiba + sinvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • FluvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • FondaparinuxanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • HeparinaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • LovastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • Óleo de peixe (ômega-3)Fitoterápicos e suplementosModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Orfenadrina + ácido acetilsalicílico + cafeínarelaxante muscularModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

  • PitavastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • Prasugrelantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • PravastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • RivaroxabanaanticoagulanteModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • RosuvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • SinvastatinaestatinaModerada

    In a double-blind, placebo-controlled trial of 8,179 statin-treated subjects with established cardiovascular disease (CVD) or diabetes plus an additional risk factor for CVD, adjudicated atrial fibrillation or atrial flutter requiring hospitalization for 24 or more hours occurred in 127 (3%) patients treated with VASCEPA compared to 84 (2%) patients receiving… (bula de Icosapente etílico, Advertências e precauções)

  • Ticagrelorantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • Tirofibanaantiagregante plaquetárioModerada

    Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time. (bula de Icosapente etílico, Interações medicamentosas)

  • VarfarinaanticoagulanteModerada

    The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

Verifique Icosapente etílico com tudo o que você toma. Adicione sua lista completa; todos os pares são verificados de uma vez.

Abrir no verificador

Não é aconselhamento médico. A gravidade reflete a redação da bula, não as suas circunstâncias. Um alerta “grave” pode ser rotina sob supervisão, e um “leve” pode ser importante em doses altas. Pergunte a um farmacêutico.